Barclays analyst James Gordon raised the firm’s price target on AstraZeneca (AZN) to 16,500 GBp from 14,000 GBp and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca announces results of Saphnelo were statistically significant
- Kennedy scales back number of vaccines recommended for children, NYT says
- AstraZeneca removed from European Conviction List at Goldman Sachs
- Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials
- MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’